- Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancerMarianne K Melnik
Grand Rapids Clinical Oncology Program, Michigan State University, East Lansing, Michigan, USA
Mol Cancer Ther 9:2423-9. 2010..The primary dose-limiting toxicities were hematologic toxicity and fatigue. These results show that the gemcitabine and etoposide combination is generally well-tolerated and exhibits a response rate similar to other published studies...